HomeIndustriesMerck Closing in on $40 Billion Acquisition of Biotech Company Seagen

Merck Closing in on $40 Billion Acquisition of Biotech Company Seagen

American multinational pharmaceutical company Merck & Co. is reportedly inching closer to the acquisition of biotech company Seagen. According to Wall Street Journal, the deal could be worth around $40 billion.

The two companies are still having active discussions but are reportedly close to settling on a $200 per share price. The goal is to wrap up the deal before July 28, when Merck is set to announce its second-quarter earnings. Merck previously bought $1 billion of Seagen’s common stock as part of the deal to co-develop a drug for breast cancer.

The news caused Seagen stock to surge to $184 at one point, representing a five percent jump compared to the closing price on Wednesday. On the other hand, Merck shares saw a minor slide dropping as low as $92.56 per share.

Based in the suburbs of Seattle, Washington, Seagen focuses on developing therapies for cancer treatment. The company is considered the leader in antibody-based treatments, and its current portfolio includes four approved drugs.

Merck, on the other hand, is facing the end of the marketing exclusivity period for its flagship cancer drug Keytruda. The patent protection of Keytruda, which brought Merck $17.2 billion in sales in 2021, is set to expire in 2028.

Fed to “Wait for Greater Clarity” Before Making Policy Adjustment Says Chair Jerome Powell

The Federal Reserve will wait to see the impact of recent sweeping tariffs on the U.S. economy before considering making policy adjustments, according to...

Oil Prices Will Decline Through 2026 According to Goldman Sachs

Oil prices will drop further this year, with the trend spilling over to 2026, according to Goldman Sachs. The investment bank forecasts that increased...

Morgan Stanley Remains Bullish on Nvidia Stock as its “Top Pick”

Shares of semiconductor giant Nvidia have had a wild ride in recent weeks. However, analysts from Morgan Stanley still believe that the stock will...